Invst LLC Acquires New Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF)

Invst LLC bought a new position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 36,000 shares of the company’s stock, valued at approximately $74,000. Invst LLC owned 0.08% of Cardiff Oncology as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Cubist Systematic Strategies LLC lifted its position in shares of Cardiff Oncology by 112.9% during the second quarter. Cubist Systematic Strategies LLC now owns 68,730 shares of the company’s stock valued at $153,000 after buying an additional 36,441 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in Cardiff Oncology in the second quarter valued at approximately $27,000. XTX Topco Ltd purchased a new position in Cardiff Oncology in the second quarter worth $185,000. Blair William & Co. IL increased its position in shares of Cardiff Oncology by 32.2% during the second quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock worth $505,000 after purchasing an additional 55,450 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Cardiff Oncology by 82.9% during the 2nd quarter. Renaissance Technologies LLC now owns 157,490 shares of the company’s stock valued at $350,000 after purchasing an additional 71,390 shares during the last quarter. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Trading Down 7.5 %

NASDAQ:CRDF opened at $2.47 on Wednesday. The company has a market capitalization of $114.98 million, a P/E ratio of -2.74 and a beta of 1.95. Cardiff Oncology, Inc. has a 12 month low of $0.94 and a 12 month high of $6.42. The firm has a fifty day simple moving average of $2.37 and a 200-day simple moving average of $3.21.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Cardiff Oncology had a negative net margin of 6,143.91% and a negative return on equity of 62.65%. The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $0.12 million. During the same quarter in the previous year, the firm posted ($0.25) EPS. Equities analysts forecast that Cardiff Oncology, Inc. will post -1 EPS for the current year.

Analysts Set New Price Targets

Separately, Craig Hallum initiated coverage on Cardiff Oncology in a research note on Friday, September 6th. They set a “buy” rating and a $8.00 target price on the stock.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.